RenovoRx, Inc.
RNXT
Positions held
Your positionsRNXT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $60.02M | Enterprise value | $50.93M | Trailing P/E | — | Forward P/E | -11.08 |
| PEG | — | Price / book | 6.68 | Beta | 0.97 | Dividend yield | 0.00% |
| Revenue growth | 115.4% | Earnings growth | — | Gross margin | 84.4% | Operating margin | -3.7% |
| Profit margin | 0.0% | ROE | -125.2% | ROA | -64.9% | Debt / equity | 0.04 |
| Current ratio | 5.74 | Free cash flow | -$6.65M | Analyst recommendation | none | Mean target | $7.13 |
| 52w high | $2.59 | 52w low | $0.70 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.9M | $0.6M | $0.2M | $0.3M | $0.4M | — |
| Op margin | -368.4% | -616.2% | -1480.3% | -1203.0% | -634.6% | — |
| Net income | -$2.9M | -$3.5M | -$2.9M | -$2.9M | -$2.9M | — |
| Gross margin | 84.3% | 85.1% | 88.2% | 80.1% | 64.0% | — |
| Gross profit | $0.8M | $0.5M | $0.2M | $0.2M | $0.3M | — |
| Operating income | -$3.3M | -$3.5M | -$3.5M | -$3.2M | -$2.7M | — |
- Revenue +61% vs prior quarter ($0.9M vs $0.6M).
- Gross margin 84.3% (was 85.1% prior quarter).
- Operating margin expanded to -368.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.1M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -1114.1% | -25511.6% | — | — | — |
| Net income | -$11.2M | -$8.8M | -$10.2M | -$9.9M | — |
| Gross margin | 70.9% | 100.0% | — | — | — |
| Gross profit | $0.8M | $0.0M | $0.0M | — | — |
| Operating income | -$12.5M | -$11.0M | -$11.4M | -$9.9M | — |
Headlines — positive tone
• [OK · fundamentals] RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...
News
2026-09-02 · RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline
2026-09-02 · RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
2026-08-21 · RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-08-17 · RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
2026-08-13 · RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...
2026-08-13 · RenovoRx, Inc. Q2 2026 Earnings Call Summary
2026-08-13 · RenovoRx Q2 Earnings Call Highlights
2026-08-12 · RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
Price (daily)
Full chart · RSI · MACD · patterns